Corrected: Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial
08/09/2026 14:14
CORRECTED-Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial Corrects headline to say Amgen-AstraZeneca drug combo, not AstraZeneca's drug combo
Sept 8 (Reuters) - AstraZeneca AZN.L said on Tuesday its cancer drug Imfinzi combined with Amgen's AMGN.O targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Leroy Leo)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally